Our previous studies [19, 24] found a high methylation status of the whole genome and hypermethylation of the Bcl-2 promoter in COPD patients and emphysema models, and demethylation treatment could protect models from emphysema. This evidence concerns the gene BCL2 and pulmonary emphysema.